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Abstract: The Transforming Growth Factor-beta (TGF-β) pathway plays essential roles in liver
development and homeostasis and become a relevant factor involved in different liver pathologies,
particularly fibrosis and cancer. The family of NADPH oxidases (NOXs) has emerged in recent
years as targets of the TGF-β pathway mediating many of its effects on hepatocytes, stellate cells
and macrophages. This review focuses on how the axis TGF-β/NOXs may regulate the biology
of different liver cells and how this influences physiological situations, such as liver regeneration,
and pathological circumstances, such as liver fibrosis and cancer. Finally, we discuss whether NOX
inhibitors may be considered as potential therapeutic tools in liver diseases.
Keywords: NOX; ROS; TGF-beta; liver regeneration; liver fibrosis; hepatocellular carcinoma;
NOX inhibitors
1. Introduction
The Transforming Growth Factor-beta (TGF-β) family of polypeptides plays important
roles in the regulation of embryogenesis and adult tissue homeostasis, and it is also impli-
cated in pathophysiological mechanisms that are the basis of several diseases, including
fibrosis and cancer [1,2]. The nicotinamide adenine dinucleotide phosphate hydrogen
(NADPH) oxidase (NOX) family produces reactive oxygen species (ROS) that play rele-
vant roles in signal transduction pathways [3]. Recent evidence indicates that NOXs may
mediate many of the TGF-β effects and, in the opposite way, NOXs could regulate TGF-β
activity [4].
2. NADPH Oxidase Family Members
In most mammals, seven isoforms of NOX have been described: NOX1–5 and two
dual oxidases (DUOX1–2). They use NADPH as an electron donor to reduce oxygen to
superoxide anion (O2−), which is then converted to hydrogen peroxide (H2O2) either
spontaneously or by enzymatic action. The first NOX identified, and the most studied
isoform, is NOX2 [5]. Due to its high level of expression in neutrophils and macrophages,
NOX2 is known as “phagocyte NADPH oxidase”. Increasingly sensitive detection methods
developed during the 1990s made it clear that O2− and H2O2 production was not only
restricted to phagocytes, but other cells/tissues also generated them [6]. Since then, the
expression of other mammalian NOX homologues has been found in various cell types and
tissues, playing roles in maintaining their normal physiology and activity. Dysregulation
in NOX expression or activation leads to several pathological consequences, such as
cardiovascular diseases, cancer, diabetes, and neurodegenerative diseases [7].
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2.1. Structural Properties
In accordance with their preserved function, NOXs share some common structural
properties: (1) the catalytic core of NOX enzymes contains six (seven for DUOX1–2)
transmembrane α-helical domains; (2) they present a NADPH-binding site and a flavine
adenine dinucleotide (FAD)-binding site at the cytosolic C- terminus; and (3) they contain
four highly conserved heme-binding histidines, two in the third and two in the fifth
transmembrane domain. Differences between NOX family members are mainly found in
their NH2-terminal structure, regulatory proteins and subunits [8,9]. Some members of
the family require, for their activation, some cytosolic subunits, which in an inactive state
remain dispersed in the cytosol but, upon activation, they assemble with transmembrane
subunits to form an active enzyme component [7]. In the case of NOX1, NOX2, and
NOX3, the complex is initially formed by the NOX subunit and p22phox, which functions
as a maturation factor required for glycosylation, stabilization, and localization of the
NOX subunit [10–12] (Figure 1). Their activation depends on the small GTPase Rac1 or
2 [13,14] and the recruitment of cytosolic proteins. NOX2 binds p67phox, p47phox [15], and
p40phox [16]. NOX1 and NOX3 bind a homolog of p67phox NOXA1 (Nox activator 1) and
an homolog of p47phox: NOXO1 (Nox organizer 1) [17–19], as well as p40phox. NOXA1
and p67phox are activators that require NOXO1 and p47phox as organizers. As a result
of activation, NOX1–3 generate O2¯ as a prime product (Figure 1) [20–22]. In the case of
NOX5, DUOX1, and DUOX2, which are the calcium-activated NOX, they are independent
of cytosolic factors but instead have EF-hands for Ca2+ sensing. While NOX5 mainly
produces O2¯ [23,24], DUOX 1–2 produce both O2¯ and H2O2 [25,26]. Finally, NOX4,
in contrast to other NOX proteins, produces large amounts of H2O2, and GTPases Rac
are not required for this activity. NOX4 associates with the protein p22phox on internal
membranes, where ROS generation occurs [27] (Figure 1). Polymerase-δ-interacting protein
2 (Poldip2) also binds to the complex, promoting NOX4 activity [28,29]. NOX4 is the
only NOX constitutively active [27] and it is able to produce H2O2 through the E-loop,
which contains a highly conserved histidine that serves as a source for protons to accelerate
spontaneous dismutation of superoxide [30].
NOX isoforms are distinctively expressed in different liver cell types, such as hep-
atocytes, hepatic stellate cells (HSC), Kupffer cells (KCs), endothelial cells (ECs), and
infiltrate leukocytes. Hepatocytes express mRNAs for NOX1, NOX2, NOX4, DUOX1, and
DUOX2; KCs, which are resident liver macrophages, express NOX2; in HSCs, NOX1, NOX2,
and NOX4 are expressed; and in ECs, NOX1, NOX2, and NOX4 are expressed (Table 1).
Nevertheless, considering that NOX1, NOX2, and NOX4 have been widely studied in
liver physiology and pathology, in this review we will focus on these three members of
the family.
2.2. Subcellular Localization of NOXs
Although an excess of ROS is toxic, physiological concentrations of ROS may function
as signaling molecules to mediate various responses, including cell migration, growth, and
apoptosis. Given that ROS are diffusible and short-lived, producing ROS at the precise
subcellular compartment is essential for stimulation of a specific redox signaling pathway,
and distinct subcellular localization would explain differences in functions [31]. Never-
theless, the lack of freely available, well-characterized, sensitive antibodies of NOXs for
investigative purposes has limited progress of the evaluation of the endogenous expression,
localization, and tissue distribution [32]. Furthermore, reported differences may vary
depending on the cell type or the overexpression system. In summary, all these obstacles
can lead to conflicting reports about the localization of NOX family members.
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Figure 1. Schematic illustration of the molecular organization of NOX isoforms and their associated subunits. The catalytic 
core of NOXs is formed by six transmembrane domains (here shown simplified). Figure was created with BioRender.com 
(accessed on 19 July 2021). 
Table 1. Cellular distribution of NOXs in the liver. 
Cell Type Type of NOX References 
Hepatocyte NOX1, NOX2, NOX4, DUOX1, DUOX2 [33] 
HSC * NOX1, NOX2, NOX4 [33,34] 
EC * NOX1, NOX2, NOX4, DUOX2 [33–36] 
KC * NOX2 [34,37] 
Liver Infiltrating Leukocyte  NOX1, NOX2 [34,38] 
* Hepatic Stellate Cell, HSC; Endothelial Cell, EC; Kupffer Cell, KC. 
2.2.1. NOX1 and NOX2 
NOX1 and NOX2 are classically NOX associated with cell plasma membrane. NOX1 
has been seen to co-localize with caveolin, a scaffolding protein associated with caveolae, 
in punctuate patches of the surface, in Vascular Smooth Muscle Cells (VSMCs) [39,40]. 
Concomitantly, in hepatocytes, NOX1 activation requires the phosphorylation of sarcoma 
kinase (Src) by TGF-β, which needs Caveolin 1 and lipid raft domains. NOX1, together 
with Src, mediate the activation of the tumor necrosis factor (TNF)-α-converting enzyme/a 
disintegrin and metalloproteinase 17 (TACE/ADAM17), and therefore increases the shed-
ding of different growth factors and cytokines, including the Epidermal Growth Factor 
Receptor (EGFR) ligands [41]. NOX1 and NOX2 produce ROS in endosomes after a hy-
poxia-reoxygenation injury, leading to c-Src activation and activity after the recruitment 
of Rac-1 and c-Src [42]. Fas ligand or TNF-α stimulation of endothelial cells promote the 
translocation of NOX2 to the lamellipodial leading edge, where ROS induce a rearrange-
ment of the cytoskeleton for cell migration [43,44]. 
Nonetheless, NOX1 has also been localized in intracellular compartments, such as in 
the nuclei of keratinocytes [45], but the mechanism involved in its translocation remains 
unknown. From the nucleus, NOX1 may mediate redox signaling of JNK and ERK cas-
cades [45], similar to what an isoform of NOX4 was demonstrated to do [31], as we will 
Figure 1. Schematic illustration of the molecular organization of NOX isoforms and their associated subunits. The catalytic
core of NOXs is formed by six transmembrane domains (here shown simplified). Figure was created with BioRender.com
(accessed on 19 July 2021).
Table 1. Cellular distribution of NOXs in the liver.
Cell Type Type of NOX References
Hepatocyte NOX1, NOX2, NOX4, DUOX1, DUOX2 [33]
HSC * NOX1, NOX2, NOX4 [33,34]
EC * NOX1, NOX2, NOX4, DUOX2 [33–36]
KC * NOX2 [34,37]
Liver Infiltrating Leukocyte NOX1, NOX2 [34,38]
* Hepatic Stellate Cell, HSC; Endothelial Cell, EC; Kupffer Cell, KC.
2.2.1. NOX1 and NOX2
NOX1 and NOX2 are classically NOX associated with cell plasma membrane. NOX1
has been seen to co-localize with caveolin, a scaffolding protein associated with caveolae,
in punctuate patches of the surface, in Vascular Smooth Muscle Cells (VSMCs) [39,40].
Concomitantly, in hepatocytes, NOX1 activation requires the phosphorylation of sarcoma
kinase (Src) by TGF-β, which needs Caveolin 1 and lipid raft domains. NOX1, together
with Src, mediate the activation of the tumor necrosis factor (TNF)-α-converting enzyme/a
disintegrin and metalloproteinase 17 (TACE/ADAM17), and therefore increases the shed-
ding of different growth factors and cytokines, including the Epidermal Growth Factor
Receptor (EGFR) ligands [41]. NOX1 and NOX2 produce ROS in endosomes after a hypoxia-
reoxygenatio injury, leading to c-Src a tivation and activity af er the recruitment of Rac-1
and c-Src [42]. Fas ligand or TNF-α stimulation of end thelial cells promote the transloca-
tion of NOX2 to the lamellipodial leading edge, where ROS induce a rearrangement of the
cytoskeleton for cell migration [43,44].
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Nonetheless, NOX1 has also been localized in intracellular compartments, such as in
the nuclei of keratinocytes [45], but the mechanism involved in its translocation remains
unknown. From the nucleus, NOX1 may mediate redox signaling of JNK and ERK cas-
cades [45], similar to what an isoform of NOX4 was demonstrated to do [31], as we will
mention later. Localization of NOX2 in perinuclear regions and in the nuclear rich fractions
have been also reported [45,46]. NOX2 may also co-localize with calreticulin, a marker of
endoplasmic reticulum (ER), in endothelial cells [46].
2.2.2. NOX4
NOX4 has been found in ER, where NOX4-generated ROS oxidize, thus inactivating,
the phosphotyrosine phosphatase PTP1B of endothelial cells [47]. It was proposed that
NOX4 is required to initiate the oxidative signaling on the ER upstream of the Unfolded
Protein Response [48]. In fibroblasts, calnexin (an ER protein) was identified as a NOX4-
interacting protein, which was required to maintain NOX4 protein levels and activity [49].
NOX4 plays a role in regulating actin cytoskeleton, whose dynamics are important in
growing cells, especially at the leading edge. H2O2 produced by ER-localized NOX4 may
be exported from the organelle to the cytoplasm where it can remodel the actin cytoskeleton.
Upon a NADPH oxidase activity blockage, the F-actin fibers network transformed into
granular F-actin aggregates, leading to a loss of cell mobility [50]. However, NOX4 has
also been seen along actin fibers in a fibrillar form, and also co-localizing with p22phox
and vinculin, marking the focal adhesions [39,51]. ROS derived from NOX4 activate Src
kinases, which are found in the focal adhesions, thus promoting their adhesion-dependent
actions [52]. NOX4 would also oxidize Cysteine residues in F-actin, specifically Cys 272
and 374, promoting the maturation of focal adhesions by means of binding the actin and
the vinculin [53].
NOX4 has also been found in the mitochondrial membrane in renal and endothelial
cells [54], where ATP negatively regulates NOX4 activity. Mitochondrial NOX4 would func-
tion as an energetic sensor of the organelle and as a metabolic checkpoint [55]. Moreover,
in cardiomyocytes, NOX4 has been described at the Mitochondria-Associated Membranes
(MAMs), the contact sites of endoplasmic reticulum and mitochondria. There, it activates
a pro-survival stress pathway that avoids cell death by inhibiting the calcium release in
MAMs with its spatially contained ROS signaling [56].
NOX4 localization has also been described to be in the nuclei of different cellular
types, such as vascular and endothelial cells, fibroblasts, or hepatocytes, where it has
been demonstrated to significantly contribute to hepatic nuclear O2− [57]. NOX4 has
also been reported to be localized within nuclei in human liver samples [58]. Although
in murine hepatocytes, NOX4 protein immunolocalized to both the outer and the inner
nuclear membrane, as well as in intranuclear inclusions, fluorescent detection of NADPH-
dependent nuclear O2− predominantly localized to the perinuclear space [57]. A 28-kDa
splice variant of NOX4, known as NOX4D, has been described in the nuclei and nucleolus
in VSMCs. This isoform, despite lacking the transmembrane domains, is functionally
active and modulates the nuclear signal transduction. NOX4D particularly increases the
phosphorylated form of ERK1/2 in the nucleus, which translates into an up-regulation of
the transcription factor Elk-1 [31] and may activate redox-sensitive transcription factors,
such as c-Fos or c-Jun, involved in growth and differentiation, or NF-κβ, implicated in
apoptosis and inflammation [59]. The generation of ROS within the nucleus may also have
a relevant role in inactivating nuclear phosphatases [60]. Unregulated nuclear ROS can
also cause DNA oxidative damage [31] and can shorten the telomere and modify the DNA
and chromosomes, triggering oxidative stress-induced senescence [59].
Finally, NOX4 is also known to be localized in the plasma membrane in VSMCs [39].
This localization was also found when bound to p22phox as a complex, where it constitu-
tively produces H2O2 [61].
A summary of all these data is represented in Figure 2.
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Figure 2. Summary of NOXs localization and NOX-dependent redox signaling through ROS. NOX1 is involved in survival 
pathways by EGFR and found in endosomes and nuclear membrane. NOX2 is found in the endoplasmic reticulum, endo-
somes and nuclear membrane, associated with the cytoskeleton. NOX2 is also associated, along with NOX4, to the plasma 
membrane and near the focal adhesions, regulating cell adhesion. Finally, NOX4 also mediates actin polymerization from 
the ER, as well as survival signaling when located in MAMs. In the mitochondria, it acts as an energetic sensor, and in the 
nuclei, is known to produce ROS in the perinuclear and nuclear space. Figure was created with BioRender.com (accessed 
on 12 July 2021). 
3. TGF-β in Human Liver Physiology and Pathology 
The three isoforms of the TGF-β family (TGF-β1, TGF-β2, and TGF-β3) are synthe-
sized as a pro-form that includes a signal peptide, a large N-terminal region known as 
latency-associated peptide (LAP), and a short C-terminal sequence that will become the 
short mature ligand. Once synthesized, it is secreted and anchored to the extracellular 
matrix (ECM) [62]. TGF-β is synthesized in excess and its activation functions as the rate-
limiting step in its bioavailability [63]. 
Upon activation of the dimeric TGF-β from the latent form, TGF-β family members 
bind to heterotetrameric transmembrane serine/threonine kinases, known as type I and 
type II receptors. TGF-β binds to homodimeric TGF-βRII, which is constitutively active 
and phosphorylates and activates homodimeric TGF-βRI. Then, activated TGF-βRI in turn 
phosphorylates SMAD2 and SMAD3 (receptor-associated SMADs, R-SMADs), which as-
sociate with SMAD4 (cooperating-SMAD), forming trimeric complexes that translocate to 
the nucleus to control the expression of target genes. Moreover, initiation and propagation 
of TGF-β signaling can be counteracted by the activity of inhibitory-SMADs: SMAD6 and 
SMAD7 [64,65] (Figure 3). In addition to the canonical SMAD pathway, TGF-β is able to 
regulate non-SMAD effectors to mediate some of its downstream biological responses, 
including NF-kB, PI3K/Akt, ERK/JNK/p38 MAPKs, as well as Rho GTPases like RhoA, 
Cdc42, and Rac1 [64,66]. 
TGF-β is secreted by several cell types and regulates many aspects of tissue and organ 
homeostasis. In the liver, TGF-β is mainly secreted by HSCs, KCs, and platelets, but it can 
be also expressed in regenerating hepatocytes [67] (Figure 3). NOX1 and NOX2 could be 
mediating the up-regulation of TGF-β expression in HSC cells [34]. In epithelial cells, TGF-
β mediates growth inhibition (Figure 3), arresting cells in the G1 phase of the cell cycle, 
Figure 2. Summary of NOXs localization and NOX-dependent redox signaling through ROS. NOX1 is involved in survival
pathways by EGFR and found in endosomes and nuclear membrane. NOX2 is found in the endoplasmic reticulum,
endosomes and nuclear membrane, associated with the cytoskeleton. NOX2 is also associated, along with NOX4, to the
plasma membrane and near the focal adhesions, regulating cell adhesion. Finally, NOX4 also mediates actin polymerization
from the ER, as well as survival signaling when located in MAMs. In the mitochondria, it acts as an energetic sensor, and in
the nuclei, is known to produce ROS in the perinuclear and nuclear space. Figure was created with BioRender.com (accessed
on 12 July 2021).
3. TGF-β in Human Liver Physiology and Pathology
The three isoforms of the TGF-β family (TGF-β1, TGF-β2, and TGF-β3) are synthesized
as a pro-form that includes a signal peptide, a large N-terminal region known as latency-
associated peptide (LAP), and a short C-terminal sequence that will become the shor
mature ligand. Once synthesized, it is secreted and anchored to the ex racellular matrix
(ECM) [62]. TGF-β is synthe ized in excess and it activation func i s as the rate-limiting
step in its bioavailability [63].
Upon activation of the di eric T F-β fro the latent form, TGF-β family members
bind to heterotetrameric transmembrane serine/threonine kinases, known as type I and
type II receptors. TGF-β binds to homodimeric TGF-βRII, which is constitutively active
and phosphorylates and activates homodimeric TGF-βRI. Then, activated TGF-βRI in
turn phosphorylates SMAD2 and SMAD3 (receptor-associated SMADs, R-SMADs), which
associate with SMAD4 (cooperating-SMAD), forming trimeric complexes that translocate to
the nucleus to control the expression of target genes. Moreover, initiation and propagation
of TGF-β signaling can be counteracted by the activity of inhibitory-SMADs: SMAD6 and
SMAD7 [64,65] (Figure 3). In addition to the canonical SMAD pathway, TGF-β is able
to regulate non-SMAD effectors to mediate some of its downstream biological responses,
including NF-kB, PI3K/Akt, ERK/JNK/p38 MAPKs, as well as Rho GTPases like Rh A,
Cdc42, and Rac1 [64,66].
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Moreover, TGF-β also participates in the maintenance of tissue homeostasis through 
its ability to induce apoptosis (Figure 3). In hepatocytes, TGF-β induces down-regulation 
of the anti-apoptotic protein Bcl-xL in rat fetal hepatocytes, in TGF-α transgenic mouse 
hepatocytes and in Hep3B cells [82–84], as well as up-regulation of pro-apoptotic proteins 
Bim and Bax in liver cells [85–87]. TGF-β-induced ROS production is required to exert its 
pro-apoptotic role in hepatocytes [71,83,88]. ROS levels depend on two different mecha-
nisms: (1) induction of NOX4 [89,90] and (2) down-regulation of antioxidant genes and 
proteins [82,90]. 
Furthermore, in fetal hepatocytes and liver tumor cells, TGF-β can also induce sur-
vival signals through activation of the EGFR pathway and c-Src phosphorylation (Figure 
3). EGF counteracts TGF-β-induced cell death effects in hepatocytes via PI3K/Akt path-
way [91,92], and blocking the EGFR signaling increases the apoptotic response to TGF-β 
Figure 3. TGF-β signaling in liver cells. TGF-β is synthesized by hepatic stellate cells, kupffer cells and platelets, and
anchored to the ECM i a latent form. Once active, TGF-β binds TGFβRII, which recruits TGFβRI, inducing Smad
phosphorylation and nuclear translocation, where transcription of target genes occurs. TGF-β-induced shedding of the EGF
family of growth factors requires the activation of TACE/ADAM17 in a Caveolin-1/Src/NOX1 dependent manner. Figure
was created with BioRender.com (accessed on 20 July 2021).
TGF-β is secreted by several cell types and regulates many aspects of tissue and
organ homeostasis. In the liver, TGF-β is mainly secreted by HSCs, KCs, and platelets,
but it can be also expressed in regenerating hepatocytes [67] (Figure 3). NOX1 and NOX2
could be mediating the up-regulation of TGF-β expression in HSC cells [34]. In epithelial
cells, TGF-β mediates growth inhibition (Figure 3), arresting cells in the G1 phase of the
cell cycle, regulating the expression and function of the cyclin-dependent kinase (CDK)
inhibitors p21cip1 (which inhibits Cyclin E/A-cdk2 complexes) [68] and p15ink4b (which
blocks Cyclin D-cdk4/6 complexes) [69,70]. In hepatocytes, TGF-β induces cell cycle arrest
and counteracts proliferative signals induced by mitogens, such as Epidermal Growth
Factor (EGF) [71,72] or Hepatocyte Growth Factor [73]. TGF-β1 induces p21 through a
p53-independent mechanism n ra hepatocytes [74], and cooperation of Smad proteins
with Sp1 induces p21 in human hepatoma HepG2 cells [75]. Moreover, TGF-β induces
down-regulation of c-Myc [76,77] and inhibition of differentiation (ID) proteins [78], which
are transcription factors involved in cellular proliferation and inhibition of differentiation,
respectively. In this regard, TGF-β treatment down-regulates c-Myc in hepatocytes [79]
and in well-differentiated hepatocellular carcinoma (HCC) cell lines in a Smad dependent
manner [80,81].
Moreover, TGF-β also participates in the maintenance of tissue homeostasis through
its ability to induce apoptosis (Figure 3). In hepatocytes, TGF-β induces down-regulation
of the anti-apoptotic protein Bcl-xL in rat fetal hepatocytes, in TGF-α transgenic mouse
hepatocytes and in Hep3B cells [82–84], as well as up-regulation of pro-apoptotic proteins
Bim and Bax in liver cells [85–87]. TGF-β-induced ROS production is required to exert its
pro-apoptotic role in hepatocytes [71,83,88]. ROS levels depend on two different mecha-
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nisms: (1) induction of NOX4 [89,90] and (2) down-regulation of antioxidant genes and
proteins [82,90].
Furthermore, in fetal hepatocytes and liver tumor cells, TGF-β can also induce survival
signals through activation of the EGFR pathway and c-Src phosphorylation (Figure 3). EGF
counteracts TGF-β-induced cell death effects in hepatocytes via PI3K/Akt pathway [91,92],
and blocking the EGFR signaling increases the apoptotic response to TGF-β [93]. As
previously mentioned, TGF-β mediates the shedding of EGFR ligands, for which it requires
the activation of the metalloprotease TACE/ADAM17 [93,94] in a Caveolin-1/Src/NOX1
dependent manner [41,95]. Importantly, TGF-β-induced activation of NOXs mediates
up-regulation of the expression of EGFR ligands, such as TGF-α and HB-EGF, through a
NF-kB-dependent mechanism [96]. Furthermore, NOX1 promotes autocrine growth of liver
tumor cells through the activation of the EGFR pathway via up-regulation of TGF-α [97].
4. Role of the TGF-β/NOX Axis in Liver Regeneration
Liver regeneration (LR) is the response to loss of hepatic tissue [98]. Hepatocytes are
the major functional cells of the liver. Indeed, in most cases, the regenerative response
is strongly triggered when there is a loss of hepatocytes at a large scale [99]. Chronic
loss of hepatocytes is observed in infectious diseases, chronic toxic conditions, ischemia
reperfusion injury, or chronic immune attacks and is accompanied by the proliferation
of the surviving cells, which may lead to development of neoplasia when occurring in
potentially genotoxic environments. The acute loss of hepatocytes, which is less common,
can be caused by ingestion of toxins (e.g., intoxication by acetaminophen), trauma, or
acute hepatitis. In all these situations, compensatory proliferation, hepatocyte death,
and inflammation, which remove dead cells and provide cytokines for repair, proceed
in tandem [100]. Nevertheless, when the regenerative process is affected, it may lead to
serious liver failure and deterioration in a patient’s general condition [101].
A transient escape of regenerative hepatocytes from TGF-β-induced growth inhibition
and apoptosis has been proposed and is achieved through reduction in the expression
of TGF-β receptors I and II [102] and the acquisition of survival signals [103], among
others. Nevertheless, a mitoinhibitory response to TGF-β is still present in regenerating
hepatocytes, since intravenous TGF-β1/2 reversibly inhibits the proliferative response
of liver to partial hepatectomy (PH) [104]. Inactivation of the TGF-β pathway by using
liver-specific Tgfbr2 knock-out mouse results in an increased proliferative response after
PH [105,106], and inhibition of TGF-β signaling also facilitates liver regeneration upon
acute dimethylnitrosamine (DMN) [107] or CCl4-induced injury [108,109].
Antioxidant treatment improves liver regeneration, indicating that elevated ROS levels
could be deleterious during this process [110,111]. Mice lacking the Nrf2 transcription
factor, in which the expression of several cytoprotective enzymes was reduced concomitant
with higher ROS levels, presented a delayed liver regeneration after PH [112]. Nevertheless,
Bai et al. described that H2O2 promotes adult hepatocytes to transition from quiescence
to proliferation in an ERK-dependent pathway, and they also reported an increase in
H2O2 early after two-thirds (2/3) PH [113]. Therefore, ROS levels probably determine
the outcome during liver regeneration, and a balanced redox status is necessary for liver
regeneration to proceed correctly.
It was initially proposed that ROS derived from a phagocytic-related NOX system are
not essential for LR after PH. Knockout mice lacking Cybb (NOX2) presented a normal
liver structure and normal TNF-α and IL-6 production after PH, as well as similar levels of
hepatocyte DNA replication as those of WT mice [114]. Regarding NOX4, its silencing in
untransformed human and mouse hepatocytes increases in vitro cell proliferative capacity
and in vivo analysis in mice revealed that NOX4 expression was down-regulated under
physiological proliferative situations of the liver, such as regeneration after PH [115].
Moreover, Nox4-deleted mice presented an accelerated recovery of the liver-to-body weight
ratio and increased survival after the surgeries [116]. Hepatocyte proliferation was higher in
Nox4-deleted mice, concomitant with increased expression of c-Myc and down-regulation
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of the TGF-β pathway. Considering that: (1) NOX4 mediates TGF-β-induced apoptosis
in hepatocytes [89]; (2) silencing of NOX4 in hepatocytes confer them higher proliferative
activity; and (3) NOX4 decreases during liver regeneration [115,116], when hepatocytes
are resistant to TGF-β, it could be speculated that some of the suppressor actions of TGF-β
during LR could be mediated by NOX4.
5. Role of TGF-β/NOX Axis in Liver Fibrosis
One of the most-studied mechanisms of fibrogenesis influenced by ROS is myofibrob-
last (MFB) activation., whereas high concentrations of ROS induce HSC death, non-toxic lev-
els of ROS stimulate the activation, proliferation, and collagen I production of HSCs [117].
Importantly, activated HSCs have increased ROS-detoxifying capacity compared to qui-
escent HSCs, which protects them from ROS-induced cell death [118]. Accordingly, MFB
activation was shown to be inhibited by antioxidants in the liver [119,120].
TGF-β-induced NOX4 regulates oxidative stress in the liver and levels of TGF-β lig-
ands and NOX4 are increased in fibrotic patients, both virus- and non-alcoholic steatohep-
atitis (NASH)-related [121,122], as well as in mice with diet-induced steatohepatitis [122].
NOX4 is required for TGF-β-induced activation of HSCs to MFBs in the liver and TGF-
β-induced HSC activation is attenuated by NOX4 down-regulation [121] (Figure 4). It is
important to highlight that during fibrosis development the highest level of NOX4 expres-
sion is found in hepatocytes, followed by MFBs and HSCs [121]. Not only NOX4, but also
NOX1 plays important roles in the progression of hepatic fibrosis, promoting proliferation
and activation of HSCs [34,123] (Figure 4). The deficiency of NOX1 or NOX4 prevents liver
inflammation and fibrosis in mice and NOX1 and NOX4 protein levels are increased in
human livers with cirrhosis compared with normal controls [124]. Regarding NOX2, it
has been proposed that it mediates profibrogenic effects in both endogenous liver cells
and bone marrow-derived cells [34]. Furthermore, recent results indicate that accelerated
fibrosis in the aged is modulated by p52Shc/NOX2. A direct activation of NOX2 in hep-
atocytes by p52Shc binding and activating the p47phox subunit results in redox stress
and accelerated fibrosis in the aged [125] (Figure 4). Finally, a role for Nox5 (which is not
expressed in mice) has been proposed, mediating the proliferation and activation of human
HSC in response to TGF-β, via p38 MAPK [126].
Hepatocyte cell death is a crucial and indirect event during fibrogenesis because apop-
totic bodies derived from damaged hepatocytes can transdifferentiate HSCs to MFBs [127].
TGF-β promotes cell death via NOX4 activation in hepatocytes and mouse hepatic oval
cells [89,128]. Moreover, NOX4 is also required for FasL or TNF-α-mediated apoptosis [129].
Cytokines through STAT5 also regulate the expression of NOX4 and key pro-apoptotic
proteins [130]. Apoptosis and phagocytosis of hepatocytes directly induce HSC activation
and initiation of fibrosis (Figure 4). NOX2, the phagocytic NADPH oxidase, plays a key role
in this process and in liver fibrogenesis in vivo, as it is required for phagocytosis of apop-
totic bodies by HSCs [131]. Furthermore, dying hepatocytes release damage-associated
molecular patterns that, upon binding to evolutionary conserved pattern recognition re-
ceptors, activate cells of the innate immune system to further stimulate inflammatory
responses, hence establishing a highly hepatotoxic feedforward cycle of inflammation and
cell death [132].
It has been suggested that TGF-β1 mediates epithelial-mesenchymal transition (EMT)
in hepatocytes, which may transdifferentiate them to MFBs, contributing to liver fibro-
sis [133]. There is no evidence for the direct involvement of NOXs in this process [121], but
it has been suggested that the EMT process is dependent on the presence of the NLRP3
(NACHT, LRR, and PYD domain-containing protein 3) receptor [134]. The EMT process
might happen in two ways: one is dependent on the inflammasome activation, when the
IL-1β executes its proinflammatory action by up-regulating the TGF-β pathway; another is
independent of the inflammasome activation, being necessary only in the presence of the
NLRP3 receptor which enhances R-Smads in the TGF-β/Smad pathway [134].
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Finally, autophagy activated by ROS is emerging as a novel mechanism of hepatic
fibrosis [135]. TGF-β-mediated ROS production, in a NOX4-dependent pathway, induces
autophagy in epithelial cells [136]. During liver fibrosis, TGF-β1 induces autophagy
through activation of the ERK and JNK signaling pathways [137], which play essential
roles in regulating autophagic processes [138], and autophagy is involved in the activation
of HSCs [137]. In fact, using cell culture and/or different animal models, numerous studies
have shown that autophagy is enhanced during the fibrogenic process and have provided
specific evidence to pinpoint the fundamental role of autophagy in HSCs activation [139].
A recent study indicates that alamandine attenuates liver fibrosis by regulating autophagy
induced by NOX4-dependent ROS [140].
6. Role of NOXs in HCC
6.1. NOXs in HCC
Liver fibrosis can lead to cirrhosis, a condition that highly predisposes a person to
develop HCC, which is the most common primary liver cancer that usually occurs under a
situation of chronic liver insults [141,142]. The onset and progression of HCC is a multistep
process usually involving subsequent mutations in genes that control cellular proliferation
and/or apoptosis in hepatocytes that are subjected to continuous inflammatory and re-
generative stimuli [143,144]. During malignant transformation and hepatic carcinogenesis,
ROS are overwhelmingly produced creating an oxidative microenvironment that may
generate different and various types of cellular stress, including DNA damage, ER stress,
cell death of damaged he atocytes, as well as oxidative stress. Members of the NADPH
oxidase family, such as NOX1, NOX2, and NOX4, have been clearly linked to produce
ROS in the liver [4], which may contribute to HCC development. Indeed, different NOX
subunits, including p47phox, p67phox, and Rac1, were found increased in pre-neoplastic
and neoplastic lesions from c-Myc, TGF-β, and c-Myc/TGF-β transgenic mice, where HCC
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developed under a context of high ROS content and decreased antioxidants in hepato-
cytes [145]. Although the exact role of NOX proteins in hepatocarcinogenesis is still under
investigation, different NOXs, produced in different liver cells, may contribute or inhibit
liver cancer progression (Figure 5), as we detail below.
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Carcinogenesis can be initiated after chronic inflammatory insults. Recent evidence in-
dicates that NOX1 expression in macrophages mediates tumor promoting activity, through
activating a ROS/MEK mechanism responsible of inflammatory cytokines production,
thereby promoting the survival and proliferation of oncogene-carrying mutant hepatocytes,
which ultimately accelerate HCC development [38]. Pharmacological inhibition of NOX1
with GKT771 during HCC progression in mice attenuates the expression of several inflam-
matory markers, angiogenesis and fibrosis, therefore reducing the pro-tumorigenic envi-
ronment [146]. Besides NOX1, NOX2-derived ROS are also involved in TLR2-dependent
M2 macrophage polarization, supporting tumor growth. In detail, hepatoma-derived
HMGB1 stimulates NOX2-derived ROS production via TLR2 to trigger autophagy forma-
tion, which leads to lysosomal degradation of NF-kB p65 and hence maintains the M2
macrophage polarization [147]. TLR4 and intestinal microbiota are also key factors in
HCC promotion, mediating increased proliferation and preventing apoptosis [148,149].
NOX2 has also been reported to be a relevant mediator of LPS/TLR-4-induced ROS produc-
tion [145,150]. Indeed, the early effects of alcohol on liver injury involve LPS stimulation of
Kupffer cells, which activates NOX2/p47phox, aiding to TNF-α release and subsequent
pro-inflammatory environment formation [151]. The generated O2− by NOX2 activation
during liver inflammation also induces hepatocyte DNA damage, which ultimately may
contribute to tumor initiation and promotion, an effect that was attenuated in p47phox-
deficient mice [152]. Importantly, an additional study using the same mouse model found
that superoxide production from Kupffer cells upon NOX2 activation is more relevant for
the promotion rather than for the initiation of hepatocarcinogenesis [153]. In agreement,
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recent studies suggested that NOX2 expression was significantly induced in HCC patients
with hepatic cirrhosis and negatively correlated with advanced tumor stage [58].
A growing body of evidence has focused on the importance of cell metabolic re-
programming during malignant transformation and HCC development to support high
proliferation rates. In this line, NOX1 has been found to support the remodeling of cel-
lular metabolism to allow available resources to be redirected towards biosynthesis of
macromolecules necessary for cell growth [154,155]. In this regard, NOX1 is involved in
glucose and glutamine catabolism, as well as in lipid, protein, and nucleotide anabolism,
thereby contributing to HCC [154]. Besides the role of NOX1 in HCC development and cell
proliferation, NOX1 has also been reported to be involved in latter stages of HCC, such
as in the regulation of cell migration. Mechanistically, NOX1 is negatively regulated by
SHMT1 (Serine hydroxymethyltransferase 1), a key enzyme involved in the regulation
of one carbon metabolism. Indeed, SHMT1 acts as tumor suppressor as inhibits HCC
metastasis, EMT and MMP2 by repressing NOX1-derived ROS production [156].
Despite NOX1 and NOX2 seeming to be inducers/promoters of HCC, recent findings
postulate NOX4 as a tumor suppressor. Indeed, NOX1 and NOX4 may have an oppo-
site prognosis in HCC patients after a hepatectomy, those patients with high NOX1 or
low NOX4 expression being associated with worse recurrence-free and overall survival
rates. [157]. An additional study has demonstrated that higher NOX4 mRNA expression
levels in HCC patients are significantly associated with prolonged overall survival, whereas
increased NOX1/NOX2 expression is significantly correlated with a poor overall survival,
therefore indicating that while NOX4 behaves as a tumor suppressor in HCC, NOX1 and
NOX2 may act as tumor promoters [155]. Importantly, NOX4 localization seems to be cru-
cial for its effects as tumor suppressor. Increased nuclear and decreased cytoplasmic NOX4
expression was found in HCC cells, as compared to non-tumoral hepatocytes, correlating
with a poorer overall survival [58]. Nuclear NOX4 localization has also been found in
chronic hepatitis C virus (HCV) infection, increasing the probability of DNA damage in
the liver, a common feature in HCC [158]. In support to its potential tumor suppressor
role, NOX4 inhibits liver cell proliferation either under physiological conditions or during
tumorigenesis. NOX4 expression is down-regulated in regeneration after PH, as well as
during diethyl-nitrosamine (DEN)-induced hepatocarcinogenesis [115]. In fact, NOX4
silencing increased cell proliferation, which is correlated with a higher percentage of cells
in S/G2/M phases of the cell cycle, the down-regulation of p21cip1, an increase in cyclin
D1, and the nuclear localization of β-catenin. Accordingly, silencing NOX4 conferred
an advantage to the human HCC cells, resulting in the earlier onset of tumor formation
and an increase in tumor size in xenograft mice [115]. In addition to differences in cell
growth, NOX4 down-regulation is also correlated with increased migratory and invasive
capabilities of HCC cells. NOX4 appears necessary to maintain parenchymal structures,
as its attenuation promotes a decrease in cell-to-cell contacts and cell-to-matrix adhesion,
correlating with an increase in actomyosin contractility and amoeboid invasion. There-
fore, the loss of NOX4 favors an epithelial to amoeboid transition, contributing to tumor
aggressiveness [159].
6.2. TGF-β, NOXs and HCC
Accumulating data indicate the importance of NOX1 and NOX4 in liver tumor cells
downstream TGF-β. As previously mentioned in hepatocytes, NOX4 mediates the pro-
apoptotic effects of TGF-β in HCC cells, involving STAT5 and PUMA, BIM, and BMF gene
up-regulation [89,130,160]. Furthermore, it has been reported that NOX4 is responsible for
TGF-β-induced senescence in HCC cells [80]. Overactivation of survival signals, such as
the MEK/ERK pathway, confers resistance to TGF-β-induced cell death by impairing the
up-regulation of NOX4 [160]. On the contrary, NOX1 is considered as a survival signal in
liver tumor cells as it has been found to play relevant roles in mediating pro-tumorigenic
TGF-β effects. NOX1 mediates autocrine growth and the survival of liver tumor cells, as
well as the anti-apoptotic signals induced by TGF-β through the transactivation of the
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EGFR pathway and TGF-β expression, involving p38 MAPK and AKT activation [97].
Indeed, NOX1 pharmacological inhibition with VAS2870 impairs cell growth and enhances
TGF-β- induced apoptosis [161]. Importantly, the inhibition of the EGFR pathway enhances
TGF-β-induced apoptosis [162] and correlates with higher levels of the NADPH oxidase
NOX4 [163]. The EGFR transactivation mediated by NOX1 results in the activation of the
NF-κB pathway which, in turn, up-regulates EGFR ligands together with TACE/ADAM17
metalloprotease activation, which are responsible for the shedding of these ligands [93,164].
Experiments of loss or gain of function in HCC cells have revealed an essential role for
clathrin in the activation of the EGFR by TGF-β, which impairs its apoptotic activity by
inhibiting the expression of its pro-apoptotic target NOX4 [165]. Overall, NOX1 and NOX4
exert opposite roles in the control of liver growth and apoptosis and their balance may
dictate cell fate [162]. Indeed, increased activation of tyrosine kinase activities or decreased
activity of protein phosphatases, such as PTP1B, increases the NOX1/NOX4 ratio, which is
responsible of NF-κB nuclear translocation that subsequently mediates resistance to TGF-β
suppressor effects [166].
7. NOX Inhibitors as Therapeutic Tools in Liver Diseases
Although inhibiting TGF-β may be considered a therapeutic tool in liver
diseases [167,168], the discovery of NOXs as TGF-β targets mediating its detrimental
effects in liver inflammation and fibrosis pushed to the challenge of using NOX inhibitors
as a more specific and adequate way to attack fibrotic pathologies [169]. However, the
development of specific inhibitors of NOX enzymes has proved difficult due to the lack
of a crystal structure for all NOX enzymes, as well as the complexity of their regulatory
interactions. Indeed, the specificity of NOX inhibitors remains controversial. Different
widely used compounds, such as diphenyleneiodonium (DPI) or VAS2870 (Vasopharm
GmbH), may inhibit all NOXs [170]. The recent development of small-molecule, more
specific NOX inhibitors in different academic institutions and private companies led to the
use of these new compounds in preclinical assays and, in some cases, clinical trials. Related
to liver pathologies, GKT137831 (Genkyotex), which was proposed as a dual NOX4/NOX1,
decreased both the apparition of fibrogenic markers and hepatocyte apoptosis in vivo upon
bile duct ligation and CCl4 treatment [122,129,171]. In the same line of evidence, therapeutic
blocking NOX1/4 with GKT137831 ameliorated cholestatic fibrosis in Mdr2−/− mice [172].
Furthermore, GKT137831 treatment also prevented liver inflammation after CCl4 injec-
tion [124] and protected from GSH depletion, caspase-3 cleavage and hepatocyte death in
acetaminophen-induced liver injury [173]. In a phase 2 clinical trial, GKT137831 was found
to be safe and well tolerated (https://clinicaltrials.gov/ct2/show/NCT02010242, accessed
on 7 July 2021). Nevertheless, recent evidence suggests that GKT137831 is not active
only on NOX enzymes, but rather has an oxidant scavenging effect [170]. In conclusion,
GKT137831, or analogs, might be promising therapeutic tools in chronic liver injury and
fibrosis; however, their mechanism of action is not fully explained by NOX inhibition and
further studies are needed to better explain its effectiveness.
Due to the evidence that indicates high NOX1 levels in HCC that correlate with a
poor prognosis [155,157], as well as the involvement of NOX1 in tumor cell proliferation
and migration [156] and macrophage-induced inflammation [38], different studies focused
on the use of NOX1 inhibitors in experimental models of hepatocarcinogenesis. DEN-
injected wild-type (WT) mice that received a NOX1 inhibitor ML171 [174] developed fewer
and smaller hepatic tumor nodules, compared to their vehicle-treated counterparts [38].
In agreement, a recent report indicated that pharmacological inhibition of NOX1 with
GKT771 (Genkyotex) during HCC progression in mice attenuate the expression of several
inflammatory markers, angiogenesis and fibrosis, therefore reducing the pro-tumorigenic
environment [146]. Despite the opposite role of NOX1 and NOX4 in HCC (the first one
promoting and the second one suppressing tumor progression), the fact that most of the
liver tumor cells express low levels of NOX4 [115] facilitates the use of general NOX
inhibitors as promising tools in the treatment of liver cancer. In this sense, VAS2870 has
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proved to be very effective in inhibiting proliferation and enhancing apoptosis induced by
a physiological stimulus, such as TGF-β in HCC cells. Nevertheless, all these studies are in
a preliminary phase and further work is necessary to fully conclude that NOXs may be
therapeutic targets in liver cancer.
8. Conclusions
Taken together the data found in the literature, there is no doubt that the cross-talk
between TGF-β and NOXs mediate relevant functions in liver cell biology, both under
physiological and pathological conditions. TGF-β-mediated activation of NOX-produced
ROS appears to be toxic in non-neoplastic conditions, contributing to hepatocyte cell death
and an inflammatory environment, which determines the transition towards a pro-fibrotic
chronic disease. The scenario becomes more complicated when considering proliferative
situations, such as liver regeneration, which occurs concomitantly to chronic liver diseases,
or hepatocarcinogenesis, where TGF-β-mediated NOX activation would play opposite
roles, depending on the member of the NOX family and the intracellular localization
where ROS are produced. Further studies are necessary to better understand the axis
TGF-β/NOX and their relationship with chronic liver diseases, fibrosis, and cancer to
validate the relevance of targeting specific NOXs in liver pathologies. Furthermore, the
development of specific inhibitors of each NOX isoform is absolutely necessary in a scenario
so complex where different NOXs could play opposite functions.
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